3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
29
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Fatigue
1
Depression
1
Advanced Prostate Cancer
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
Docetaxel
6
avelumab
5
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Abiraterone Acetate
×
90 days
×
Clear all
No trials found.